NEWS
Smart Healthcare
- Publish Date：2025-01-15
NYCU Demonstrates Research Excellence in 2024 with Breakthrough Medical Imaging Technologies
(Photo credit: Getty Images)
Edited by Chance Lai
______
______
National Yang Ming Chiao Tung University (NYCU) has once again showcased its research prowess in 2024. The university successfully obtained Quality Management System (QMS) certification for three cutting-edge intelligent medical imaging systems: the AI Brain Tumor Detection System, the Critical Care Early Warning Platform, and the Anesthetic Transmission Puncture Needle.
This achievement positions NYCU as one of the few institutions in Taiwan holding multiple QMS certifications alongside licenses for manufacturing and selling medical devices. It underscores NYCU’s leading role in medical device R&D and commercialization while strengthening the foundation for industry-academia collaboration.
This achievement positions NYCU as one of the few institutions in Taiwan holding multiple QMS certifications alongside licenses for manufacturing and selling medical devices. It underscores NYCU’s leading role in medical device R&D and commercialization while strengthening the foundation for industry-academia collaboration.
Certified Innovations: A Leap in Medical Technology
The newly certified systems include the AI Brain Tumor Detection System (DeepBT Detector), developed by Professor Yu-Te Wu’s team at the Institute of Biophotonics. It stands as Taiwan’s first Class II software-based medical device approved for multi-tumor annotation. The Critical Care Early Warning Platform (NEXUS-AI), an AI-driven model designed by Professor Albert Chih-Chieh Yang’s team from the NYCU School of Medicine and Taipei Veterans General Hospital (TVGH), enables early-stage sepsis prediction.
Meanwhile, the Anesthetic Transmission Puncture Needle, engineered by Professor Hui-Hua Kenny Chiang’s team from the Department of Biomedical Engineering, resolves imaging and procedural challenges in regional anesthesia, especially for obese patients.
Professor Chun-Li Lin, Director of NYCU Medical Device Innovation and Translation Center, highlighted the university’s commitment to narrowing the gap between academic research and industrial application.
Professor Lin explained that traditional medical device development in universities and hospitals often overlooks key aspects such as manufacturing, quality systems, and preclinical regulatory testing, leading to commercialization and clinical adoption challenges. By securing multiple QMS certifications, NYCU enables direct technology transfer to industry partners, significantly reducing the time-to-market for medical innovations.
Transforming R&D into Market-Ready Solutions
NYCU Medical Device Innovation and Translation Center adheres to a “clinical needs-driven, application-oriented” philosophy. While prioritizing technological breakthroughs, the center emphasizes the development of safe and effective medical products. Its portfolio includes advanced implants, intelligent medical devices, and diagnostic software. With multiple Class I and Class II medical device registrations already secured, the center’s latest QMS certifications mark a significant milestone.
These certifications streamline the path from design to market, cutting development timelines by one to two years on average and addressing longstanding barriers to academic commercialization. This acceleration enhances the value of technology transfer and sets a new benchmark for industry-academia cooperation.
Future Prospects: Innovating for Global Impact
Currently, several additional products are being prepared for QMS certification. NYCU is dedicated to advancing innovative medical devices and fostering industry partnerships to create safe, effective, and competitive medical solutions. NYCU continues to inject transformative innovation into the global healthcare sector through these efforts.
Related Image(s)：
